Physician profile
Robert D Levy
NPI 1861495517
$23,570.79
in general payments reported to CMS, 2019-2025
27 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $533 · 2021: $905 · 2022: $859 · 2023: $1,071 · 2024: $1,022 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $17,250.00 | 2019 | |
| Alcon Vision LLC | $807.91 | 2019-2025 | Total30, Tryptyr, Precision7 |
| Bausch & Lomb Americas INC. | $735.13 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $557.44 | 2019-2024 | Acuvue |
| Allergan, INC. | $494.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $474.96 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $303.34 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $302.73 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $292.41 | 2021-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $282.96 | 2020-2022 | |
| Vertos Medical, INC. | $275.88 | 2019 | |
| Abb Con-Cise Optical Group LLC | $253.51 | 2019-2025 | Contact Lens, Spectacle Lenses |
| Abbvie INC. | $252.52 | 2022-2025 | |
| Rxsight INC | $230.85 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $211.29 | 2024-2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $171.63 | 2019-2021 | |
| Coopervision INC. | $146.56 | 2019-2024 | Myday Contact Lens, Paragon Crt |
| Amgen INC. | $139.08 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $139.06 | 2019-2021 | |
| Sight Sciences, INC. | $114.12 | 2025 | Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $40.38 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Visioneering Technologies, INC. | $17.09 | 2020 | |
| Maculogix, INC. | $15.82 | 2019 | |
| Ocular Therapeutix, INC. | $15.75 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $14.81 | 2023 | Tepezza |
| Harrow Eye, LLC | $13.91 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.